RPRX
Royalty Pharma plc
Price Chart
Latest Quote
$52.96
-0.74 (-1.38%)
Current Price
| Previous Close | $53.70 |
| Open | $54.38 |
| Day High | $54.38 |
| Day Low | $51.15 |
| Volume | 8,608,503 |
Stock Information
| Quarterly Dividend / Yield | $0.94 / 1.77% |
| Shares Outstanding | 443.27M |
| Quarterly Dividend Yield | 1.77% |
| Quarterly Dividend | $0.94 |
| Total Debt | $8.97B |
| Cash Equivalents | $608.29M |
| Revenue | $2.44B |
| Net Income | $826.29M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $30.50B |
| P/E Ratio | 27.87 |
| EPS (TTM) | $1.90 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $34.89B |
| Sales | $2.44B |
| Income | $826.29M |
| Book/sh | $15.53 |
| Cash/sh | $1.37 |
| Employees | 100 |
Financial Ratios
| Quick Ratio | 2.64 |
| Current Ratio | 2.66 |
| Debt/Eq | 90.32 |
| EPS Growth TTM | 23.10% |
Returns & Margins
| ROA | 5.54% |
| ROE | 13.77% |
| Gross Margin | 115.00% |
| Operating Margin | 100.30% |
| Profit Margin | 33.86% |
Ownership
| Insider Ownership | 6.53% |
| Institutional Ownership | 88.07% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 9.43 |
| PEG | 1.98 |
| P/S | 12.50 |
| P/B | 3.41 |
Analyst Data
| Recommendation | none |
| Target Price | $59.25 |
Technical Indicators
| SMA20 | $54.57 |
| SMA50 | $51.90 |
| SMA200 | $43.02 |
| RSI | 35.42 |
| ATR | 1.4507 |
| Shares Float | 413.19M |
| Short Float | 2.65% |
| Short Ratio | 2.76 |
| Volatility | 0.42 |
| Rel Volume | 1.95 |
Performance History
| Week | -4.21% |
| Month | +1.05% |
| Quarter | +16.83% |
| 6 Months | +39.32% |
| YTD | +37.60% |
| Year | +56.53% |
| 3 Years | +77.00% |
| 5 Years | +32.62% |
| 10 Years | +35.87% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $52.96 | 8,608,500 |
| 2026-06-17 | $53.70 | 3,145,400 |
| 2026-06-16 | $54.21 | 2,841,800 |
| 2026-06-15 | $54.27 | 1,948,700 |
| 2026-06-12 | $54.87 | 3,185,500 |
| 2026-06-11 | $55.29 | 3,073,000 |
| 2026-06-10 | $54.52 | 2,228,900 |
| 2026-06-09 | $55.63 | 3,747,000 |
| 2026-06-08 | $54.86 | 3,714,700 |
| 2026-06-05 | $55.87 | 6,027,400 |
| 2026-06-04 | $55.02 | 4,588,600 |
| 2026-06-03 | $54.97 | 4,469,700 |
| 2026-06-02 | $54.01 | 3,567,900 |
| 2026-06-01 | $55.18 | 4,352,700 |
| 2026-05-29 | $55.76 | 17,987,900 |
| 2026-05-28 | $54.48 | 3,084,500 |
| 2026-05-27 | $53.97 | 3,075,800 |
| 2026-05-26 | $53.86 | 2,758,200 |
| 2026-05-22 | $54.50 | 3,053,800 |
| 2026-05-21 | $53.55 | 2,842,900 |
| 2026-05-20 | $53.06 | 2,868,400 |
| 2026-05-19 | $52.41 | 3,808,500 |
About Royalty Pharma plc
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has research and development funding collaboration to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases. The company was founded in 1996 and is based in New York, New York.
đ° Latest News
Branded Pharmaceuticals Stocks Q1 Recap: Benchmarking Royalty Pharma (NASDAQ:RPRX)
StockStory âĸ 2026-06-15T16:28:07Z
This Royalty Pharma Insider Reduced Their Stake By 10%
Simply Wall St. âĸ 2026-06-12T14:00:06Z
3 Unpopular Stocks Weâre Skeptical Of
StockStory âĸ 2026-06-12T12:13:20Z
Why Is Agenus (AGEN) Down 9.6% Since Last Earnings Report?
Zacks âĸ 2026-06-10T15:30:04Z
Royalty Pharma (RPRX): Buy, Sell, or Hold Post Q1 Earnings?
StockStory âĸ 2026-06-09T14:06:14Z
Mattel Stock Is Down 24%. Here's What a $50.9 Million Exit Could Mean
Motley Fool âĸ 2026-05-30T00:34:40Z
Royalty Pharma (RPRX) Valuation Check After Strong Share Price Momentum And Royalty Growth Potential
Simply Wall St. âĸ 2026-05-25T23:11:29Z
3 Mid-Cap Stocks We Steer Clear Of
StockStory âĸ 2026-05-20T10:04:55Z
Royalty Pharma (RPRX) Benefits from Biotech Funding Gap with Rising Returns and Market Dominance
Insider Monkey âĸ 2026-05-18T12:32:13Z
Royalty Pharmaâs Q1 Earnings Call: Our Top 5 Analyst Questions
StockStory âĸ 2026-05-16T09:24:55Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $2,378,193,000 | $2,263,576,000 | $2,354,554,000 | $2,237,215,000 |
| Operating Revenue | $2,378,193,000 | $2,263,576,000 | $2,354,554,000 | $2,237,215,000 |
| Expenses | ||||
| Interest Expense | $307,664,000 | $225,512,000 | $187,187,000 | $187,961,000 |
| Total Expenses | $818,675,000 | $971,132,000 | $862,404,000 | $1,314,323,000 |
| Other Income Expense | $38,747,000 | $216,538,000 | $322,834,000 | $-583,202,000 |
| Other Non Operating Income Expenses | $-14,349,000 | $-1,528,000 | $-21,737,000 | $-14,755,000 |
| Net Non Operating Interest Income Expense | $-274,073,000 | $-178,169,000 | $-114,896,000 | $-109,626,000 |
| Interest Expense Non Operating | $307,664,000 | $225,512,000 | $187,187,000 | $187,961,000 |
| Operating Expense | $818,675,000 | $971,132,000 | $862,404,000 | $1,314,323,000 |
| Other Operating Expenses | $-295,838,000 | $732,461,000 | $560,656,000 | $904,244,000 |
| General And Administrative Expense | $573,481,000 | $236,671,000 | $249,748,000 | $227,303,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $770,947,000 | $858,983,000 | $1,134,834,000 | $42,832,000 |
| Net Interest Income | $-274,073,000 | $-178,169,000 | $-114,896,000 | $-109,626,000 |
| Interest Income | $33,591,000 | $47,343,000 | $72,291,000 | $78,335,000 |
| Normalized Income | $746,940,000 | $670,528,000 | $819,145,000 | $602,306,000 |
| Net Income From Continuing And Discontinued Operation | $770,947,000 | $858,983,000 | $1,134,834,000 | $42,832,000 |
| Total Operating Income As Reported | $1,559,518,000 | $1,292,444,000 | $1,492,150,000 | $307,065,000 |
| Average Dilution Earnings | $234,575,000 | $276,893,000 | $392,726,000 | - |
| Net Income Common Stockholders | $770,947,000 | $858,983,000 | $1,134,834,000 | $42,832,000 |
| Net Income | $770,947,000 | $858,983,000 | $1,134,834,000 | $42,832,000 |
| Net Income Including Noncontrolling Interests | $1,324,192,000 | $1,330,813,000 | $1,700,088,000 | $230,064,000 |
| Net Income Continuous Operations | $1,324,192,000 | $1,330,813,000 | $1,700,088,000 | $230,064,000 |
| Pretax Income | $1,324,192,000 | $1,330,813,000 | $1,700,088,000 | $230,064,000 |
| Earnings From Equity Interest | $29,089,000 | $29,611,000 | $28,882,000 | $-8,973,000 |
| Interest Income Non Operating | $33,591,000 | $47,343,000 | $72,291,000 | $78,335,000 |
| Operating Income | $1,559,518,000 | $1,292,444,000 | $1,492,150,000 | $922,892,000 |
| Special Income Charges | - | $0 | $0 | $-615,827,000 |
| Depreciation Amortization Depletion Income Statement | - | $0 | $0 | $5,670,000 |
| Depreciation And Amortization In Income Statement | - | $0 | $0 | $5,670,000 |
| Amortization Of Intangibles Income Statement | - | $0 | $0 | $5,670,000 |
| Per Share | ||||
| Diluted EPS | $1.37 | $1.45 | $2.53 | $0.10 |
| Basic EPS | $1.80 | $1.93 | $2.54 | $0.10 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $1,611,701,000 | $1,367,870,000 | $1,571,586,000 | $983,169,000 |
| Total Unusual Items | $24,007,000 | $188,455,000 | $315,689,000 | $-559,474,000 |
| Total Unusual Items Excluding Goodwill | $24,007,000 | $188,455,000 | $315,689,000 | $-559,474,000 |
| Reconciled Depreciation | $3,852,000 | $0 | $0 | $5,670,000 |
| EBITDA (Bullshit earnings) | $1,635,708,000 | $1,556,325,000 | $1,887,275,000 | $423,695,000 |
| EBIT | $1,631,856,000 | $1,556,325,000 | $1,887,275,000 | $418,025,000 |
| Diluted Average Shares | $564,000,000 | $594,000,000 | $602,900,000 | $437,972,000 |
| Basic Average Shares | $428,669,000 | $445,985,000 | $447,601,000 | $437,963,000 |
| Diluted NI Availto Com Stockholders | $1,005,522,000 | $1,135,876,000 | $1,527,560,000 | $42,832,000 |
| Minority Interests | $-553,245,000 | $-471,830,000 | $-565,254,000 | $-187,232,000 |
| Tax Provision | $0 | $0 | $0 | $0 |
| Gain On Sale Of Security | $24,007,000 | $188,455,000 | $315,689,000 | $56,353,000 |
| Provision For Doubtful Accounts | $89,032,000 | $0 | $0 | - |
| Research And Development | $452,000,000 | $2,000,000 | $52,000,000 | $177,106,000 |
| Selling General And Administration | $573,481,000 | $236,671,000 | $249,748,000 | $227,303,000 |
| Other Gand A | $573,481,000 | $236,671,000 | $249,748,000 | $227,303,000 |
| Write Off | - | $0 | $0 | $615,827,000 |
| Amortization | - | $0 | $0 | $5,670,000 |
| Otherunder Preferred Stock Dividend | - | - | $-392,726,000 | - |
Fetched: 2026-06-19
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $5,552,266,000 | $6,946,581,000 | $6,526,497,000 | $5,628,150,000 |
| Total Assets | $19,620,780,000 | $18,222,715,000 | $16,381,851,000 | $16,813,466,000 |
| Total Non Current Assets | $18,092,689,000 | $16,420,576,000 | $15,107,658,000 | $14,258,558,000 |
| Other Non Current Assets | $79,293,000 | $33,534,000 | $6,522,000 | $29,629,000 |
| Investmentin Financial Assets | $16,798,794,000 | $16,007,618,000 | $14,725,242,000 | $13,831,754,000 |
| Goodwill And Other Intangible Assets | $924,634,000 | $0 | - | $0 |
| Current Assets | $1,528,091,000 | $1,802,139,000 | $1,274,193,000 | $2,554,908,000 |
| Other Current Assets | $6,893,000 | $4,187,000 | $18,040,000 | $90,520,000 |
| Receivables | $29,316,000 | $26,956,000 | $22,405,000 | $36,597,000 |
| Other Receivables | $29,316,000 | $26,956,000 | $22,405,000 | $36,597,000 |
| Cash Cash Equivalents And Short Term Investments | $1,491,882,000 | $1,770,996,000 | $1,233,748,000 | $2,427,791,000 |
| Cash And Cash Equivalents | $618,696,000 | $929,026,000 | $477,010,000 | $1,710,751,000 |
| Other Intangible Assets | - | - | - | - |
| Debt | ||||
| Net Debt | $8,332,221,000 | $6,683,400,000 | $5,658,275,000 | $5,405,571,000 |
| Total Debt | $8,950,917,000 | $7,612,426,000 | $6,135,285,000 | $7,116,322,000 |
| Long Term Debt And Capital Lease Obligation | $8,570,917,000 | $6,614,653,000 | $6,135,285,000 | $6,118,810,000 |
| Long Term Debt | $8,570,917,000 | $6,614,653,000 | $6,135,285,000 | $6,118,810,000 |
| Current Debt And Capital Lease Obligation | $380,000,000 | $997,773,000 | - | $997,512,000 |
| Current Debt | $380,000,000 | $997,773,000 | - | $997,512,000 |
| Other Current Borrowings | - | $997,773,000 | - | $997,512,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $9,905,841,000 | $7,880,349,000 | $6,297,562,000 | $7,288,093,000 |
| Total Non Current Liabilities Net Minority Interest | $9,269,630,000 | $6,626,733,000 | $6,136,185,000 | $6,121,310,000 |
| Other Non Current Liabilities | $120,843,000 | $12,080,000 | $900,000 | $2,500,000 |
| Current Liabilities | $636,211,000 | $1,253,616,000 | $161,377,000 | $1,166,783,000 |
| Other Current Liabilities | $53,164,000 | $68,600,000 | $11,375,000 | $12,400,000 |
| Payables And Accrued Expenses | $203,047,000 | $187,243,000 | $150,002,000 | $156,871,000 |
| Interest Payable | $110,818,000 | $98,062,000 | $51,682,000 | $54,162,000 |
| Payables | $92,229,000 | $89,181,000 | $98,320,000 | $102,709,000 |
| Dividends Payable | $72,825,000 | $75,811,000 | $83,155,000 | $94,803,000 |
| Accounts Payable | $19,404,000 | $13,370,000 | $15,165,000 | $7,906,000 |
| Equity | ||||
| Common Stock Equity | $6,476,900,000 | $6,946,581,000 | $6,526,497,000 | $5,628,150,000 |
| Total Equity Gross Minority Interest | $9,714,939,000 | $10,342,366,000 | $10,084,289,000 | $9,525,373,000 |
| Stockholders Equity | $6,476,900,000 | $6,946,581,000 | $6,526,497,000 | $5,628,150,000 |
| Retained Earnings | $2,356,318,000 | $2,845,653,000 | $2,517,583,000 | $1,964,689,000 |
| Long Term Equity Investment | $289,968,000 | $379,424,000 | $375,894,000 | $397,175,000 |
| Gains Losses Not Affecting Retained Earnings | - | $0 | $0 | $0 |
| Other Equity Adjustments | - | - | - | - |
| Investments In Other Ventures Under Equity Method | - | - | - | - |
| Other | ||||
| Ordinary Shares Number | $428,669,000 | $445,985,000 | $446,692,000 | $443,166,000 |
| Share Issued | $428,669,000 | $445,985,000 | $446,692,000 | $443,166,000 |
| Tangible Book Value | $5,552,266,000 | $6,946,581,000 | $6,526,497,000 | $5,628,150,000 |
| Invested Capital | $15,427,817,000 | $14,559,007,000 | $12,661,782,000 | $12,744,472,000 |
| Working Capital | $891,880,000 | $548,523,000 | $1,112,816,000 | $1,388,125,000 |
| Total Capitalization | $15,047,817,000 | $13,561,234,000 | $12,661,782,000 | $11,746,960,000 |
| Minority Interest | $3,238,039,000 | $3,395,785,000 | $3,557,792,000 | $3,897,223,000 |
| Treasury Stock | $2,612,000 | $2,662,000 | $2,629,000 | $2,806,000 |
| Additional Paid In Capital | $4,123,088,000 | $4,103,482,000 | $4,011,435,000 | $3,666,160,000 |
| Capital Stock | $106,000 | $108,000 | $108,000 | $107,000 |
| Common Stock | $106,000 | $108,000 | $108,000 | $107,000 |
| Employee Benefits | $577,870,000 | $0 | - | - |
| Current Accrued Expenses | $110,818,000 | $98,062,000 | $51,682,000 | $54,162,000 |
| Investments And Advances | $17,088,762,000 | $16,387,042,000 | $15,101,136,000 | $14,228,929,000 |
| Available For Sale Securities | $16,798,794,000 | $16,007,618,000 | $14,725,242,000 | $13,831,754,000 |
| Goodwill | $924,634,000 | $0 | - | - |
| Other Short Term Investments | $873,186,000 | $841,970,000 | $756,738,000 | $717,040,000 |
Fetched: 2026-06-19
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $2,489,823,000 | $2,768,986,000 | $2,987,802,000 | $2,143,980,000 |
| Operating Activities | ||||
| Operating Cash Flow | $2,489,823,000 | $2,768,986,000 | $2,987,802,000 | $2,143,980,000 |
| Cash Flow From Continuing Operating Activities | $2,489,823,000 | $2,768,986,000 | $2,987,802,000 | $2,143,980,000 |
| Operating Gains Losses | $-2,314,248,000 | $-2,367,488,000 | $-2,542,325,000 | $-2,172,057,000 |
| Investing Activities | ||||
| Investing Cash Flow | $-1,614,180,000 | $-2,678,115,000 | $-2,072,789,000 | $-1,029,421,000 |
| Cash Flow From Continuing Investing Activities | $-1,614,180,000 | $-2,678,115,000 | $-2,072,789,000 | $-1,029,421,000 |
| Net Other Investing Changes | $-280,259,000 | $-72,961,000 | $-14,438,000 | - |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-1,227,383,000 | $-229,651,000 | $-304,759,000 | $0 |
| Financing Cash Flow | $-1,185,973,000 | $361,145,000 | $-2,148,754,000 | $-944,856,000 |
| Cash Flow From Continuing Financing Activities | $-1,185,973,000 | $361,145,000 | $-2,148,754,000 | $-944,856,000 |
| Net Other Financing Charges | $-534,812,000 | $-503,974,000 | $-485,668,000 | $-611,534,000 |
| Cash Dividends Paid | $-378,253,000 | $-376,465,000 | $-358,327,000 | $-333,322,000 |
| Common Stock Dividend Paid | $-378,253,000 | $-376,465,000 | $-358,327,000 | $-333,322,000 |
| Net Common Stock Issuance | $-1,227,383,000 | $-229,651,000 | $-304,759,000 | $0 |
| Dividends Received Cfi | $105,149,000 | $23,641,000 | $43,882,000 | $0 |
| Dividend Received Cfo | $13,396,000 | $13,396,000 | $18,823,000 | $39,142,000 |
| Issuance Of Capital Stock | - | - | - | $0 |
| Common Stock Issuance | - | - | - | $0 |
| Other | ||||
| Repayment Of Debt | $-2,275,000,000 | $0 | $-1,350,000,000 | $0 |
| Issuance Of Debt | $3,229,475,000 | $1,471,235,000 | $350,000,000 | $0 |
| End Cash Position | $618,696,000 | $929,026,000 | $477,010,000 | $1,710,751,000 |
| Beginning Cash Position | $929,026,000 | $477,010,000 | $1,710,751,000 | $1,541,048,000 |
| Changes In Cash | $-310,330,000 | $452,016,000 | $-1,233,741,000 | $169,703,000 |
| Common Stock Payments | $-1,227,383,000 | $-229,651,000 | $-304,759,000 | $0 |
| Net Issuance Payments Of Debt | $954,475,000 | $1,471,235,000 | $-1,000,000,000 | $0 |
| Net Long Term Debt Issuance | $954,475,000 | $1,471,235,000 | $-1,000,000,000 | $0 |
| Long Term Debt Payments | $-2,275,000,000 | $0 | $-1,350,000,000 | $0 |
| Long Term Debt Issuance | $3,229,475,000 | $1,471,235,000 | $350,000,000 | $0 |
| Net Investment Purchase And Sale | $-1,364,654,000 | $-2,617,840,000 | $-2,089,691,000 | $-1,019,525,000 |
| Sale Of Investment | $566,502,000 | $118,361,000 | $25,831,000 | $1,545,543,000 |
| Purchase Of Investment | $-1,931,156,000 | $-2,736,201,000 | $-2,115,522,000 | $-2,565,068,000 |
| Net Business Purchase And Sale | $-74,416,000 | $-10,955,000 | $-12,542,000 | $-9,896,000 |
| Purchase Of Business | $-74,416,000 | $-10,955,000 | $-12,542,000 | $-9,896,000 |
| Change In Working Capital | $-17,151,000 | $53,383,000 | $5,382,000 | $32,662,000 |
| Change In Other Current Liabilities | $-2,350,000 | $0 | $0 | - |
| Change In Other Current Assets | $-7,447,000 | $13,844,000 | $3,147,000 | $38,654,000 |
| Change In Payables And Accrued Expense | $-4,994,000 | $44,090,000 | $3,756,000 | $-1,248,000 |
| Change In Accrued Expense | $8,934,000 | $46,380,000 | $-2,480,000 | $-3,534,000 |
| Change In Interest Payable | $8,934,000 | $46,380,000 | $-2,480,000 | $-3,534,000 |
| Change In Payable | $-13,928,000 | $-2,290,000 | $6,236,000 | $2,286,000 |
| Change In Account Payable | $-13,928,000 | $-2,290,000 | $6,236,000 | $2,286,000 |
| Change In Receivables | $-2,360,000 | $-4,551,000 | $-1,521,000 | $-4,744,000 |
| Other Non Cash Items | $3,396,694,000 | $3,004,077,000 | $3,242,821,000 | $2,486,258,000 |
| Stock Based Compensation | $289,894,000 | $2,344,000 | $2,357,000 | $2,170,000 |
| Provisionand Write Offof Assets | $-206,806,000 | $732,461,000 | $560,656,000 | $904,244,000 |
| Depreciation Amortization Depletion | $3,852,000 | $0 | $0 | $5,670,000 |
| Depreciation And Amortization | $3,852,000 | $0 | $0 | $5,670,000 |
| Depreciation | $3,852,000 | $0 | $0 | - |
| Earnings Losses From Equity Investments | $-29,089,000 | $-29,611,000 | $-28,882,000 | $8,973,000 |
| Gain Loss On Investment Securities | $-2,285,159,000 | $-2,337,877,000 | $-2,513,443,000 | $-2,181,449,000 |
| Net Income From Continuing Operations | $1,324,192,000 | $1,330,813,000 | $1,700,088,000 | $230,064,000 |
| Asset Impairment Charge | - | $0 | $0 | $615,827,000 |
| Amortization Cash Flow | - | $0 | $0 | $5,670,000 |
| Amortization Of Intangibles | - | $0 | $0 | $5,670,000 |
| Net Short Term Debt Issuance | - | - | $0 | $0 |
| Short Term Debt Payments | - | - | $-350,000,000 | $0 |
| Short Term Debt Issuance | - | - | $350,000,000 | $0 |
| Unrealized Gain Loss On Investment Securities | - | - | - | - |
Fetched: 2026-06-19